TaiGen Successfully Completes TG-1000 Phase III Study ...Middle East

PR Newswire - News
TAIPEI, April 17, 2024 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") announces today that the business partner, Joincare Pharmaceutical, has completed the unblinding of influenza antiviral TG-1000 phase III study. Preliminary data shows that the median time to...

Hence then, the article about taigen successfully completes tg 1000 phase iii study was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( TaiGen Successfully Completes TG-1000 Phase III Study )

Apple Storegoogle play

Last updated :

Also on site :